A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer.
This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck(HN), and salivary gland cancer(SGC). Patients with progressing incurable HN and SGC ECOG ≤1, no prior immunotherapy, RECIST1.1 measurable disease, normal organ function were eligible. Pembrolizumab 200mg was given IV q21 days, and vorinostat 400 mg given orally 5 days on and 2 days off at the start of each 21 day cycle. Primary endpoints were safety and objective response rates. From 11/2015 to 8/2017, 25 HN and 25 SGC pts were enrolled. Median age was 61(range 33-86) yrs, 39(78%) were male, 21(62%) were never smokers, 27(54%) had ECOG 0. In HN, 13(52%) were p16+ oropharynx. Most common SGC histologies were adenoid cystic(ACC) 12(48%), acinic cell(AciC) 3(12%), mucoepidermoid 3(12%). Adverse events (AEs) in all pts were: 27(54%) Grade≥1, 18(36%) Grade≥3. The most common AEs in all pts were renal insufficiency 7(14%), fatigue 6(12%) and nausea 3(6%). There were 3(12%) deaths on study. Responses in HN were: complete response(CR) 0, partial response(PR) 8 (32%), stable disease(SD) 5(20%). Efficacy in SGC:CR 0, PR 4(16%) in 1 lymphoepithelioma-like carcinoma (LEL-C)C, 2 AciC and 1 ACC, SD 14(56%). In the HN group, median follow up(mFUP) was 12.6 months, median overall survival(mOS) was 12.6 months, and median progression free survival (mPFS) was 4.5 months. In SGC, mFUP was 13.1 months, mOS was 14.0 months, and mPFS was 6.9 months. This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone.